July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
AR-1105 Dexamethasone Extended Release and Pharmacokinetics in the Non-Human Primate
Author Affiliations & Notes
  • Janet Tully
    Aerie Pharmaceuticals, Durham, North Carolina, United States
  • Stuart Williams
    Aerie Pharmaceuticals, Durham, North Carolina, United States
  • Dustin Melton
    Aerie Pharmaceuticals, Durham, North Carolina, United States
  • RiLee Robeson
    Envisia Therapeutics, Durham, North Carolina, United States
  • Mari Yang
    Envisia Therapeutics, Durham, North Carolina, United States
  • Rozemarijn Verhoeven
    Aerie Pharmaceuticals, Durham, North Carolina, United States
  • Footnotes
    Commercial Relationships   Janet Tully, Aerie Pharmaceuticals (E); Stuart Williams, Aerie Pharmaceuticals (E); Dustin Melton, Aerie Pharmaceuticals (E); RiLee Robeson, Envisia Therapeutics (E); Mari Yang, Envisia Therapeutics (E); Rozemarijn Verhoeven, Aerie Pharmaceuticals (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5673. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Janet Tully, Stuart Williams, Dustin Melton, RiLee Robeson, Mari Yang, Rozemarijn Verhoeven; AR-1105 Dexamethasone Extended Release and Pharmacokinetics in the Non-Human Primate. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5673.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Intravitreal dexamethasone is used in the treatment of diabetic macular edema (DME), retinal vein occlusion (RVO), and uveitis. An extended release biodegradable IVT implant with a dose sparing, linear release rate has the potential for an improved safety profile and extended duration of effect compared with marketed products. Here we demonstrate the ability to fabricate biodegradable, dexamethasone-containing IVT implants that provide extended release of dexamethasone in the monkey for at least six months.

Methods : AR-1105 was designed for intravitreal delivery of extended release dexamethasone using the PRINT technology. Drug content and in vitro release were measured by RP-HPLC. In vitro release rates were measured at 37C in 1X PBS, pH 7.4 with 0.1% Triton X-100. Pharmacokinetics and tolerability of AR-1105 was evaluated in the cynomolgous monkey for up to six months post-dose. Ophthalmic exams and intraocular pressure (IOP) measurements were conducted, and ocular matrices, remaining implants, and plasma were processed and analyzed by LC-MS/MS at terminal time points.

Results : In vitro release of dexamethasone was demonstrated for up to six months. In the monkey, dexamethasone exposure was demonstrated for at least six months. Therapeutically relevant dexamethasone concentrations were present in target tissues of retina, choroid, and vitreous at all time points studied, while anterior chamber and systemic exposure was minimal. There was no test article-related effect on IOP.

Conclusions : AR-1105 provided extended release of dexamethasone from biodegradeable, intravitreal implants in vitro and in the monkey through six months, and was well tolerated. Intravitreal administration of a dose sparing dexamethasone implant resulted in drug delivery to the posterior target tissues with minimal anterior chamber or systemic exposure and excellent ocular tolerability, and may thus decrease the risk of adverse effects.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×